CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
Public ClinicalTrials.gov record NCT02189629. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Study identification
- NCT ID
- NCT02189629
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Galderma R&D
- Industry
- Enrollment
- 453 participants
Conditions and interventions
Conditions
Interventions
- CD5789 (trifarotene) Drug
Drug
Eligibility (public fields only)
- Age range
- 9 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 22, 2015
- Primary completion
- Feb 22, 2017
- Completion
- Feb 22, 2017
- Last update posted
- Nov 13, 2019
2015 – 2017
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Galderma Investigational Site | Mobile | Alabama | 36608 | — |
| Galderma Investigational Site | Rogers | Arkansas | 72758 | — |
| Galderma Investigational Site | Sacramento | California | 95819 | — |
| Galderma Investigational Site | San Diego | California | 92123 | — |
| Galderma Investigational Site | Miami | Florida | 33175 | — |
| Galderma Investigational Site | Miramar | Florida | 33027 | — |
| Galderma Investigational Site | Newnan | Georgia | 30277 | — |
| Galderma Investigational Site | Louisville | Kentucky | 40241 | — |
| Galderma Investigational Site | Albuquerque | New Mexico | 87107 | — |
| Galderma Investigational Site | New York | New York | 10155 | — |
| Galderma Investigational Site | High Point | North Carolina | 27262 | — |
| Galderma Investigational Site | Beachwood | Ohio | 44122 | — |
| Galderma Investigational Site | Portland | Oregon | 97210 | — |
| Galderma Investigational Site | Knoxville | Tennessee | 37922 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02189629, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 13, 2019 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02189629 live on ClinicalTrials.gov.